Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
41
Fortrea Clinical Research Unit Inc ( Site 0001)
Daytona Beach, Florida, United States
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin
Blood samples will be collected to determine the AUC0-inf of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide
Blood samples will be collected to determine the AUC0-inf of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 1 month
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 2 weeks
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin
Blood samples will be collected to determine the AUC0-last of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Blood samples will be collected to determine the AUC0-last of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin
Blood samples will be collected to determine the AUC0-24 of rosuvastatin.
Time frame: At designated time points (up to approximately 24 hours)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Furosemide
Blood samples will be collected to determine the AUC0-24 of furosemide.
Time frame: At designated time points (up to approximately 24 hours)
Maximum Plasma Concentration (Cmax) of Rosuvastatin
Blood samples will be collected to determine the Cmax of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Maximum Plasma Concentration (Cmax) of Furosemide
Blood samples will be collected to determine the Cmax of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Rosuvastatin
Blood samples will be collected to determine the Tmax of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Furosemide
Blood samples will be collected to determine the Tmax of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Rosuvastatin
Blood samples will be collected to determine the t1/2 of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Furosemide
Blood samples will be collected to determine the t1/2 of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Rosuvastatin
Blood samples will be collected to determine the CL/F of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Furosemide
Blood samples will be collected to determine the CL/F of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Rosuvastatin
Blood samples will be collected to determine the Vz/F of rosuvastatin.
Time frame: At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Furosemide
Blood samples will be collected to determine the Vz/F of furosemide.
Time frame: At designated time points (up to approximately 2 weeks)